10 XP 0   0   5  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

LEXX (Lexaria Bioscience Corp) Stock Analysis
Buy, Hold or Sell?

Let's analyze Lexaria Bioscience Corp together

I guess you are interested in Lexaria Bioscience Corp. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Lexaria Bioscience Corp’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Lexaria Bioscience Corp’s Price Targets

I'm going to help you getting a better view of Lexaria Bioscience Corp. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Lexaria Bioscience Corp

I send you an email if I find something interesting about Lexaria Bioscience Corp.

1. Quick Overview

1.1. Quick analysis of Lexaria Bioscience Corp (30 sec.)










1.2. What can you expect buying and holding a share of Lexaria Bioscience Corp? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
2.5%

What is your share worth?

Current worth
$0.26
Expected worth in 1 year
$0.03
How sure are you?
35.0%

+ What do you gain per year?

Total Gains per Share
$-0.23
Return On Investment
-19.4%

For what price can you sell your share?

Current Price per Share
$1.21
Expected price per share
$1.088 - $1.911
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Lexaria Bioscience Corp (5 min.)




Live pricePrice per Share (EOD)
$1.21
Intrinsic Value Per Share
$-8.04 - $-4.52
Total Value Per Share
$-7.77 - $-4.25

2.2. Growth of Lexaria Bioscience Corp (5 min.)




Is Lexaria Bioscience Corp growing?

Current yearPrevious yearGrowGrow %
How rich?$5.1m$5.4m$1.7m24.3%

How much money is Lexaria Bioscience Corp making?

Current yearPrevious yearGrowGrow %
Making money-$2.8m-$1.2m-$1.6m-57.4%
Net Profit Margin-1,952.0%8,187.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Lexaria Bioscience Corp (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#619 / 853

Most Revenue
#568 / 853

Most Profit
#338 / 853

Most Efficient
#715 / 853
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Lexaria Bioscience Corp?

Welcome investor! Lexaria Bioscience Corp's management wants to use your money to grow the business. In return you get a share of Lexaria Bioscience Corp.

First you should know what it really means to hold a share of Lexaria Bioscience Corp. And how you can make/lose money.

Speculation

The Price per Share of Lexaria Bioscience Corp is $1.21. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Lexaria Bioscience Corp.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Lexaria Bioscience Corp, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.26. Based on the TTM, the Book Value Change Per Share is $-0.06 per quarter. Based on the YOY, the Book Value Change Per Share is $0.07 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Lexaria Bioscience Corp.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.19-16.0%-0.15-12.0%-0.06-5.1%-0.10-8.1%-0.09-7.1%-0.07-5.4%
Usd Book Value Change Per Share-0.08-6.7%-0.06-4.8%0.076.0%-0.02-1.3%0.010.4%0.010.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.1%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.08-6.7%-0.06-4.8%0.076.2%-0.02-1.3%0.010.4%0.010.4%
Usd Price Per Share1.02-2.12-2.47-2.34-2.89-1.77-
Price to Earnings Ratio-1.32--4.12--11.75--7.88--4.64--4.18-
Price-to-Total Gains Ratio-12.51--9.15-17.81--9.57--25.97--22.13-
Price to Book Ratio3.86-5.61-8.79-7.61-7.34-7.05-
Price-to-Total Gains Ratio-12.51--9.15-17.81--9.57--25.97--22.13-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.21
Number of shares826
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.060.01
Usd Total Gains Per Share-0.060.01
Gains per Quarter (826 shares)-48.364.41
Gains per Year (826 shares)-193.4417.63
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-193-2031178
20-387-39623326
30-580-58935044
40-774-78246662
50-967-97558380
60-1161-1168610098
70-1354-13617116116
80-1548-15548133134
90-1741-17479149152
100-1934-194010166170

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%1.039.00.02.5%5.073.00.06.4%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%6.014.00.030.0%14.026.00.035.0%26.050.02.033.3%
Dividend per Share0.00.04.00.0%1.00.011.08.3%1.00.019.05.0%1.00.039.02.5%1.00.077.01.3%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%6.014.00.030.0%14.026.00.035.0%26.050.02.033.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Lexaria Bioscience Corp compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.082-0.059-28%0.073-212%-0.016-80%0.005-1722%0.005-1682%
Book Value Per Share--0.2640.370-29%0.281-6%0.312-15%0.368-28%0.234+13%
Current Ratio--3.90211.240-65%38.603-90%23.027-83%29.621-87%24.967-84%
Debt To Asset Ratio--0.2340.158+48%0.065+259%0.103+127%0.083+180%0.156+50%
Debt To Equity Ratio--0.2840.186+53%0.065+339%0.116+145%0.093+205%0.253+12%
Dividend Per Share----0%0.002-100%0.001-100%0.000-100%0.000-100%
Enterprise Value--23000840.00046650971.000-51%52276957.020-56%50110595.153-54%61947236.866-63%38036475.596-40%
Eps---0.194-0.146-25%-0.062-68%-0.099-49%-0.086-56%-0.065-66%
Ev To Ebitda Ratio---1.533-4.588+199%-13.226+763%-8.769+472%-5.596+265%-4.823+215%
Ev To Sales Ratio--33.04797.579-66%-286.752+968%30.582+8%229.004-86%173.860-81%
Free Cash Flow Per Share---0.183-0.125-32%-0.062-66%-0.086-53%-0.074-60%-0.051-72%
Free Cash Flow To Equity Per Share---0.097-0.048-51%0.068-243%-0.010-90%0.006-1652%0.005-2141%
Gross Profit Margin--1.0001.0000%1.013-1%1.0040%1.027-3%1.072-7%
Intrinsic Value_10Y_max---4.517----------
Intrinsic Value_10Y_min---8.038----------
Intrinsic Value_1Y_max---0.241----------
Intrinsic Value_1Y_min---0.426----------
Intrinsic Value_3Y_max---0.885----------
Intrinsic Value_3Y_min---1.615----------
Intrinsic Value_5Y_max---1.724----------
Intrinsic Value_5Y_min---3.165----------
Market Cap23666632.000+16%19950384.00041465504.000-52%48359633.020-59%45740330.153-56%56523251.916-65%34716455.346-43%
Net Profit Margin---21.776-19.520-10%81.879-127%10.720-303%-7.074-68%-19.291-11%
Operating Margin----14.2610%69.762-100%8.296-100%-8.9010%-17.6480%
Operating Ratio--22.55420.555+10%-68.941+406%-5.567+125%11.449+97%22.465+0%
Pb Ratio4.581+16%3.8615.608-31%8.786-56%7.609-49%7.345-47%7.045-45%
Pe Ratio-1.561-19%-1.316-4.120+213%-11.752+793%-7.878+499%-4.642+253%-4.184+218%
Price Per Share1.210+16%1.0202.120-52%2.472-59%2.339-56%2.890-65%1.775-43%
Price To Free Cash Flow Ratio-1.651-19%-1.392-4.917+253%-12.185+776%-8.780+531%-11.744+744%-8.739+528%
Price To Total Gains Ratio-14.845-19%-12.514-9.153-27%17.811-170%-9.568-24%-25.972+108%-22.131+77%
Quick Ratio--3.37110.404-68%37.007-91%22.032-85%28.845-88%23.413-86%
Return On Assets---0.562-0.349-38%-0.252-55%-0.300-47%-0.251-55%-0.366-35%
Return On Equity---0.682-0.403-41%-0.249-63%-0.323-53%-0.269-61%-0.448-34%
Total Gains Per Share---0.082-0.059-28%0.074-209%-0.015-81%0.005-1627%0.005-1636%
Usd Book Value--5166521.0007245099.000-29%5486928.500-6%6097129.500-15%7205137.800-28%4577717.275+13%
Usd Book Value Change Per Share---0.082-0.059-28%0.073-212%-0.016-80%0.005-1722%0.005-1682%
Usd Book Value Per Share--0.2640.370-29%0.281-6%0.312-15%0.368-28%0.234+13%
Usd Dividend Per Share----0%0.002-100%0.001-100%0.000-100%0.000-100%
Usd Enterprise Value--23000840.00046650971.000-51%52276957.020-56%50110595.153-54%61947236.866-63%38036475.596-40%
Usd Eps---0.194-0.146-25%-0.062-68%-0.099-49%-0.086-56%-0.065-66%
Usd Free Cash Flow---3583953.000-2442283.750-32%-1219119.750-66%-1685149.667-53%-1440994.550-60%-1000176.650-72%
Usd Free Cash Flow Per Share---0.183-0.125-32%-0.062-66%-0.086-53%-0.074-60%-0.051-72%
Usd Free Cash Flow To Equity Per Share---0.097-0.048-51%0.068-243%-0.010-90%0.006-1652%0.005-2141%
Usd Market Cap23666632.000+16%19950384.00041465504.000-52%48359633.020-59%45740330.153-56%56523251.916-65%34716455.346-43%
Usd Price Per Share1.210+16%1.0202.120-52%2.472-59%2.339-56%2.890-65%1.775-43%
Usd Profit---3789092.000-2847698.250-25%-1212468.500-68%-1927809.417-49%-1683876.750-56%-1279867.850-66%
Usd Revenue--174000.000153980.750+13%94211.250+85%109880.750+58%115964.650+50%83374.575+109%
Usd Total Gains Per Share---0.082-0.059-28%0.074-209%-0.015-81%0.005-1627%0.005-1636%
 EOD+5 -3MRQTTM+4 -32YOY+5 -353Y+5 -355Y+5 -3410Y+8 -31

3.3 Fundamental Score

Let's check the fundamental score of Lexaria Bioscience Corp based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.561
Price to Book Ratio (EOD)Between0-14.581
Net Profit Margin (MRQ)Greater than0-21.776
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.371
Current Ratio (MRQ)Greater than13.902
Debt to Asset Ratio (MRQ)Less than10.234
Debt to Equity Ratio (MRQ)Less than10.284
Return on Equity (MRQ)Greater than0.15-0.682
Return on Assets (MRQ)Greater than0.05-0.562
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Lexaria Bioscience Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5060.289
Ma 20Greater thanMa 501.003
Ma 50Greater thanMa 1000.930
Ma 100Greater thanMa 2000.972
OpenGreater thanClose1.470
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Lexaria Bioscience Corp

Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. Its DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, creams, lotions, and skin patches; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Fundamental data was last updated by Penke on 2025-09-04 03:49:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Lexaria Bioscience Corp earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Lexaria Bioscience Corp to theΒ Biotechnology industry mean.
  • A Net Profit Margin of -2,177.6%Β means thatΒ $-21.78 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Lexaria Bioscience Corp:

  • The MRQ is -2,177.6%. The company is making a huge loss. -2
  • The TTM is -1,952.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-2,177.6%TTM-1,952.0%-225.7%
TTM-1,952.0%YOY8,187.9%-10,139.9%
TTM-1,952.0%5Y-707.4%-1,244.6%
5Y-707.4%10Y-1,929.1%+1,221.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,177.6%-85.5%-2,092.1%
TTM-1,952.0%-171.0%-1,781.0%
YOY8,187.9%-210.0%+8,397.9%
3Y1,072.0%-289.9%+1,361.9%
5Y-707.4%-381.1%-326.3%
10Y-1,929.1%-520.3%-1,408.8%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Lexaria Bioscience Corp is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Lexaria Bioscience Corp to theΒ Biotechnology industry mean.
  • -56.2% Return on Assets means thatΒ Lexaria Bioscience Corp generatedΒ $-0.56 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Lexaria Bioscience Corp:

  • The MRQ is -56.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -34.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-56.2%TTM-34.9%-21.3%
TTM-34.9%YOY-25.2%-9.8%
TTM-34.9%5Y-25.1%-9.8%
5Y-25.1%10Y-36.6%+11.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-56.2%-11.9%-44.3%
TTM-34.9%-11.9%-23.0%
YOY-25.2%-11.2%-14.0%
3Y-30.0%-12.0%-18.0%
5Y-25.1%-11.7%-13.4%
10Y-36.6%-13.8%-22.8%
4.3.1.3. Return on Equity

Shows how efficient Lexaria Bioscience Corp is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Lexaria Bioscience Corp to theΒ Biotechnology industry mean.
  • -68.2% Return on Equity means Lexaria Bioscience Corp generated $-0.68Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Lexaria Bioscience Corp:

  • The MRQ is -68.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -40.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-68.2%TTM-40.3%-28.0%
TTM-40.3%YOY-24.9%-15.3%
TTM-40.3%5Y-26.9%-13.3%
5Y-26.9%10Y-44.8%+17.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-68.2%-14.2%-54.0%
TTM-40.3%-15.2%-25.1%
YOY-24.9%-15.3%-9.6%
3Y-32.3%-16.9%-15.4%
5Y-26.9%-17.5%-9.4%
10Y-44.8%-19.6%-25.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Lexaria Bioscience Corp.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Lexaria Bioscience Corp is operatingΒ .

  • Measures how much profit Lexaria Bioscience Corp makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Lexaria Bioscience Corp to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Lexaria Bioscience Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-1,426.1%+1,426.1%
TTM-1,426.1%YOY6,976.2%-8,402.3%
TTM-1,426.1%5Y-890.1%-536.0%
5Y-890.1%10Y-1,764.8%+874.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--154.1%+154.1%
TTM-1,426.1%-280.2%-1,145.9%
YOY6,976.2%-268.7%+7,244.9%
3Y829.6%-281.5%+1,111.1%
5Y-890.1%-350.8%-539.3%
10Y-1,764.8%-530.7%-1,234.1%
4.3.2.2. Operating Ratio

Measures how efficient Lexaria Bioscience Corp is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 22.55 means that the operating costs are $22.55 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Lexaria Bioscience Corp:

  • The MRQ is 22.554. The company is inefficient in keeping operating costs low. -1
  • The TTM is 20.555. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ22.554TTM20.555+1.999
TTM20.555YOY-68.941+89.496
TTM20.5555Y11.449+9.106
5Y11.44910Y22.465-11.016
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ22.5541.952+20.602
TTM20.5552.974+17.581
YOY-68.9413.047-71.988
3Y-5.5673.835-9.402
5Y11.4494.924+6.525
10Y22.4656.864+15.601
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Lexaria Bioscience Corp.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Lexaria Bioscience Corp is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 3.90Β means the company has $3.90 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Lexaria Bioscience Corp:

  • The MRQ is 3.902. The company is very able to pay all its short-term debts. +2
  • The TTM is 11.240. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.902TTM11.240-7.338
TTM11.240YOY38.603-27.362
TTM11.2405Y29.621-18.381
5Y29.62110Y24.967+4.654
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.9023.480+0.422
TTM11.2403.790+7.450
YOY38.6034.104+34.499
3Y23.0274.609+18.418
5Y29.6215.764+23.857
10Y24.9676.154+18.813
4.4.3.2. Quick Ratio

Measures if Lexaria Bioscience Corp is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Lexaria Bioscience Corp to theΒ Biotechnology industry mean.
  • A Quick Ratio of 3.37Β means the company can pay off $3.37 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Lexaria Bioscience Corp:

  • The MRQ is 3.371. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 10.404. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.371TTM10.404-7.033
TTM10.404YOY37.007-26.603
TTM10.4045Y28.845-18.441
5Y28.84510Y23.413+5.433
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3712.938+0.433
TTM10.4043.291+7.113
YOY37.0073.928+33.079
3Y22.0324.393+17.639
5Y28.8455.837+23.008
10Y23.4136.549+16.864
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Lexaria Bioscience Corp.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Lexaria Bioscience CorpΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Lexaria Bioscience Corp to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.23Β means that Lexaria Bioscience Corp assets areΒ financed with 23.4% credit (debt) and the remaining percentage (100% - 23.4%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Lexaria Bioscience Corp:

  • The MRQ is 0.234. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.158. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.234TTM0.158+0.076
TTM0.158YOY0.065+0.093
TTM0.1585Y0.083+0.074
5Y0.08310Y0.156-0.073
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2340.339-0.105
TTM0.1580.359-0.201
YOY0.0650.334-0.269
3Y0.1030.341-0.238
5Y0.0830.349-0.266
10Y0.1560.379-0.223
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Lexaria Bioscience Corp is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Lexaria Bioscience Corp to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 28.4% means that company has $0.28 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Lexaria Bioscience Corp:

  • The MRQ is 0.284. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.186. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.284TTM0.186+0.098
TTM0.186YOY0.065+0.121
TTM0.1865Y0.093+0.093
5Y0.09310Y0.253-0.160
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2840.391-0.107
TTM0.1860.436-0.250
YOY0.0650.436-0.371
3Y0.1160.461-0.345
5Y0.0930.461-0.368
10Y0.2530.514-0.261
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Lexaria Bioscience Corp generates.

  • Above 15 is considered overpriced butΒ always compareΒ Lexaria Bioscience Corp to theΒ Biotechnology industry mean.
  • A PE ratio of -1.32 means the investor is paying $-1.32Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Lexaria Bioscience Corp:

  • The EOD is -1.561. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.316. Based on the earnings, the company is expensive. -2
  • The TTM is -4.120. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.561MRQ-1.316-0.245
MRQ-1.316TTM-4.120+2.803
TTM-4.120YOY-11.752+7.633
TTM-4.1205Y-4.642+0.522
5Y-4.64210Y-4.184-0.458
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.561-2.539+0.978
MRQ-1.316-2.361+1.045
TTM-4.120-2.657-1.463
YOY-11.752-3.749-8.003
3Y-7.878-3.883-3.995
5Y-4.642-6.353+1.711
10Y-4.184-7.102+2.918
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Lexaria Bioscience Corp:

  • The EOD is -1.651. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.392. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.917. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.651MRQ-1.392-0.259
MRQ-1.392TTM-4.917+3.526
TTM-4.917YOY-12.185+7.268
TTM-4.9175Y-11.744+6.826
5Y-11.74410Y-8.739-3.004
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.651-3.411+1.760
MRQ-1.392-2.951+1.559
TTM-4.917-3.614-1.303
YOY-12.185-4.421-7.764
3Y-8.780-5.258-3.522
5Y-11.744-8.587-3.157
10Y-8.739-9.639+0.900
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Lexaria Bioscience Corp is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 3.86 means the investor is paying $3.86Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Lexaria Bioscience Corp:

  • The EOD is 4.581. Based on the equity, the company is fair priced.
  • The MRQ is 3.861. Based on the equity, the company is fair priced.
  • The TTM is 5.608. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD4.581MRQ3.861+0.719
MRQ3.861TTM5.608-1.746
TTM5.608YOY8.786-3.178
TTM5.6085Y7.345-1.737
5Y7.34510Y7.045+0.299
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.5812.206+2.375
MRQ3.8612.027+1.834
TTM5.6082.194+3.414
YOY8.7862.425+6.361
3Y7.6092.571+5.038
5Y7.3453.805+3.540
10Y7.0454.462+2.583
4.6.2. Total Gains per Share

2.4. Latest News of Lexaria Bioscience Corp

Does Lexaria Bioscience Corp still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Lexaria Bioscience Corp to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-09-04
16:39
Interesting T Put And Call Options For October 24thRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Lexaria Bioscience Corp.

4.8.1. Institutions holding Lexaria Bioscience Corp

Institutions are holding 11.744% of the shares of Lexaria Bioscience Corp.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-06-30Invenomic Capital Management, LP2.56380.0248501468-48479-8.8152
2025-03-31Geode Capital Management, LLC0.8817017245757783.4665
2025-06-30Vanguard Group Inc0.6828013355456834.4443
2025-06-30The Toronto-Dominion Bank0.68060.000213312531002.3842
2025-03-31State Street Corp0.200903930100
2025-03-31Wealth Enhancement Advisory Services, LLC0.15830.00013095920867.2247
2025-03-31Byrne Asset Management LLC0.14780.03652890515905122.3462
2025-03-31BlackRock Inc0.140302744500
2025-03-31HighTower Advisors, LLC0.10740.000121000-23-0.1094
2025-03-31Northern Trust Corp0.09401838900
2025-03-31Bank of Montreal0.0717014033330.2357
2025-03-31BMO Capital Markets Corp.0.0717014033330.2357
2025-03-31Royal Bank of Canada0.03720728300
2025-06-30Oakworth Capital Inc0.02560.0003500000
2025-03-31Wells Fargo & Co0.010202000-2000-50
2025-06-30Tower Research Capital LLC0.010.0001196466651.3097
2025-03-31Advisor Group Holdings, Inc.0.009701890-400-17.4672
2025-03-31Federation des caisses Desjardins du Quebec0.00203823820
2025-03-31Bank of America Corp0.0007013375.5556
2025-06-30Gables Capital Management Inc0.000101300
Total 5.89650.06211153334-17229-1.5%

4.9.2. Funds holding Lexaria Bioscience Corp

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Invenomic Institutional1.41520.03012767947777239.0771
2025-07-31Vanguard Institutional Extnd Mkt Idx Tr0.64750.000112663832882.6656
2025-06-30Fidelity Extended Market Index0.44440.000286921-227-0.2605
2025-06-30Fidelity Total Market Index0.134402629400
2025-06-30Fidelity Series Total Market Index0.113502220300
2025-06-30Extended Equity Market Fund K0.11210.000121928-438-1.9583
2025-06-30Spartan Extended Market Index Pool F0.09630.00021882600
2025-06-30NT Ext Equity Mkt Idx Fd - L0.06260.00011224900
2025-06-30Northern Trust Extended Eq Market Idx0.06260.00011224900
2025-06-30Fidelity Nasdaq Composite Index0.05940.00011162200
2025-07-31Vanguard U.S. Eq Idx Β£ Acc0.052201020400
2025-06-30Spartan Total Market Index Pool G0.04510881800
2025-06-30NT Ext Equity Mkt Idx Fd - NL0.02840.0001554700
2025-06-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.0220.00014307-11-0.2547
2025-06-30NT Ext Eq Mkt Indx Fd DC Lending Tier 50.01770.0001345651417.4711
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T30.01490.0003291929190
2025-06-30Extended Equity Market Fund M0.01410.00012762-40-1.4276
2025-07-31State St US Extended Mkt Indx NL Cl C0.01020.0001200000
2025-03-31SSgA U.S. Total Market Index Strategy0.00430838182.1951
2025-06-30Northern Trust Wilshire 50000.003059300
Total 3.35990.0318657168+83795+12.8%

5.3. Insider Transactions

Insiders are holding 7.135% of the shares of Lexaria Bioscience Corp.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-07-30Christopher BunkaBUY119000.91
2025-07-29Christopher BunkaBUY156000.92
2025-07-29John Martin DochertyBUY53760.93
2025-07-29Richard ChristopherBUY150000.91
2025-07-29Vanessa CarleBUY7500.91
2025-07-29William Edward MckechnieBUY50000.91
2024-12-02Richard ChristopherBUY228282.24
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-05-31. Currency in USD. All numbers in thousands.

Summary
Total Assets6,741
Total Liabilities1,575
Total Stockholder Equity5,552
 As reported
Total Liabilities 1,575
Total Stockholder Equity+ 5,552
Total Assets = 6,741

Assets

Total Assets6,741
Total Current Assets5,807
Long-term Assets935
Total Current Assets
Cash And Cash Equivalents 4,592
Short-term Investments 34
Net Receivables 358
Other Current Assets 823
Total Current Assets  (as reported)5,807
Total Current Assets  (calculated)5,807
+/-0
Long-term Assets
Property Plant Equipment 354
Intangible Assets 516
Long-term Assets Other 64
Long-term Assets  (as reported)935
Long-term Assets  (calculated)935
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,488
Long-term Liabilities87
Total Stockholder Equity5,552
Total Current Liabilities
Short-term Debt 30
Accounts payable 1,447
Other Current Liabilities 1,458
Total Current Liabilities  (as reported)1,488
Total Current Liabilities  (calculated)2,935
+/- 1,447
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt87
Long-term Liabilities  (as reported)87
Long-term Liabilities  (calculated)87
+/-0
Total Stockholder Equity
Common Stock20
Retained Earnings -60,765
Accumulated Other Comprehensive Income -81
Other Stockholders Equity 66,378
Total Stockholder Equity (as reported)5,552
Total Stockholder Equity (calculated)5,552
+/-0
Other
Capital Stock20
Cash and Short Term Investments 4,625
Common Stock Shares Outstanding 18,298
Liabilities and Stockholders Equity 6,741
Net Debt -4,475
Net Invested Capital 5,552
Net Working Capital 4,319
Property Plant and Equipment Gross 911
Short Long Term Debt Total 117



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-05-312025-02-282024-11-302024-08-312024-05-312024-02-292023-11-302023-08-312023-05-312023-02-282022-11-302022-08-312022-05-312022-02-282021-11-302021-08-312021-05-312021-02-282020-11-302020-08-312020-05-312020-02-292019-11-302019-08-312019-05-312019-02-282018-11-302018-08-312018-05-312018-02-282017-11-302017-08-312017-05-312017-02-282016-11-302016-08-312016-05-312016-02-292015-11-302015-08-312015-05-312015-02-282014-11-302014-08-312014-05-312014-02-282013-11-302013-08-312013-05-312013-02-282012-11-302012-08-312012-05-312012-02-292011-11-302011-08-312011-05-312011-02-282010-11-302010-08-312010-05-312010-02-282009-11-302009-08-312009-05-312009-02-282008-11-302008-05-312008-02-292007-11-302007-08-312007-05-312007-02-282006-11-302006-08-312006-05-312006-02-282005-11-30
> Total Assets 
1,192
1,164
1,114
1,114
2,719
2,475
2,439
3,191
3,796
4,236
3,819
3,763
3,220
3,250
3,250
3,329
3,398
3,339
3,418
3,278
3,717
3,513
3,865
4,339
4,228
4,131
4,224
4,192
3,923
3,799
3,683
3,573
3,560
4,838
4,566
2,251
1,211
1,199
712
496
389
331
567
1,137
869
3,144
2,860
2,497
2,841
2,709
2,432
3,544
4,274
3,457
2,675
2,746
1,986
3,320
2,828
2,174
12,172
10,548
13,267
11,746
11,415
9,138
7,834
6,213
4,855
5,240
3,084
3,627
6,352
10,018
8,868
9,794
8,678
6,741
6,7418,6789,7948,86810,0186,3523,6273,0845,2404,8556,2137,8349,13811,41511,74613,26710,54812,1722,1742,8283,3201,9862,7462,6753,4574,2743,5442,4322,7092,8412,4972,8603,1448691,1375673313894967121,1991,2112,2514,5664,8383,5603,5733,6833,7993,9234,1924,2244,1314,2284,3393,8653,5133,7173,2783,4183,3393,3983,3293,2503,2503,2203,7633,8194,2363,7963,1912,4392,4752,7191,1141,1141,1641,192
   > Total Current Assets 
216
114
7
7
1,299
438
47
983
134
359
357
691
245
331
331
372
478
443
493
140
464
304
730
264
323
265
517
473
285
216
182
146
165
1,467
1,201
2,198
1,158
1,158
675
456
337
279
510
1,067
804
3,079
2,795
2,417
2,745
2,587
2,284
3,231
3,641
2,608
1,819
1,911
1,180
2,528
1,926
1,308
10,946
9,686
12,443
10,901
10,572
8,291
6,978
5,359
4,004
4,235
2,200
2,694
5,417
9,093
7,898
8,826
7,724
5,807
5,8077,7248,8267,8989,0935,4172,6942,2004,2354,0045,3596,9788,29110,57210,90112,4439,68610,9461,3081,9262,5281,1801,9111,8192,6083,6413,2312,2842,5872,7452,4172,7953,0798041,0675102793374566751,1581,1582,1981,2011,467165146182216285473517265323264730304464140493443478372331331245691357359134983474381,29977114216
       Cash And Cash Equivalents 
210
114
7
7
1,285
427
29
920
78
102
246
670
198
240
240
330
446
416
431
63
280
127
494
31
140
121
16
181
39
45
28
66
29
952
578
431
792
832
260
84
40
37
93
124
524
2,789
2,533
2,210
2,318
2,063
1,727
2,645
3,093
1,996
1,285
1,333
740
2,034
1,294
525
9,347
8,109
10,918
9,682
8,359
7,051
5,813
4,533
3,272
3,164
1,352
1,954
4,705
8,459
6,500
8,078
6,469
4,592
4,5926,4698,0786,5008,4594,7051,9541,3523,1643,2724,5335,8137,0518,3599,68210,9188,1099,3475251,2942,0347401,3331,2851,9963,0932,6451,7272,0632,3182,2102,5332,78952412493374084260832792431578952296628453918116121140314941272806343141644633024024019867024610278920294271,28577114210
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18
10
71
71
75
64
23
24
18
19
44
471
401
834
493
552
288
347
270
268
270
126
72
88
46
56
40
74
34
3474405646887212627026827034728855249383440147144191824236475717110180000000000000000000000000000000000000000000000000
       Net Receivables 
0
0
0
0
13
5
10
35
38
243
112
16
37
91
91
42
22
20
57
75
176
170
232
231
176
140
498
291
240
167
152
131
131
100
99
75
35
22
31
35
44
15
131
649
24
28
45
72
188
268
266
215
219
226
273
326
227
254
314
427
628
954
342
462
507
155
202
286
86
172
175
535
357
208
154
263
331
358
358331263154208357535175172862862021555074623429546284273142542273262732262192152662681887245282464913115443531223575991001311311521672402914981401762312321701767557202242919137161122433835105130000
       Other Current Assets 
6
0
0
0
0
6
7
29
18
14
3
6
10
0
0
0
9
7
5
2
9
6
4
2
6
4
3
1
6
4
3
2
5
415
367
1,673
253
225
215
149
112
101
151
287
226
105
150
116
354
324
194
183
149
123
69
96
65
89
182
185
364
170
319
237
1,122
757
577
260
370
630
547
132
267
380
1,188
444
850
823
8238504441,1883802671325476303702605777571,122237319170364185182896596691231491831943243541161501052262871511011121492152252531,6733674155234613462469257900010631418297600006
   > Long-term Assets 
976
1,050
1,107
1,107
1,420
2,037
2,393
2,207
3,662
3,878
3,461
3,072
2,974
2,920
2,920
2,957
2,921
2,896
2,925
3,138
3,252
3,210
3,135
4,075
3,906
3,867
3,707
3,719
3,638
3,583
3,501
3,427
3,395
3,371
3,366
53
53
41
37
40
52
52
56
70
65
65
65
80
96
122
148
313
633
849
856
835
806
792
902
867
1,226
862
824
845
842
846
856
854
851
1,004
933
933
935
925
970
968
929
935
9359299689709259359339331,0048518548568468428458248621,22686790279280683585684963331314812296806565657056525240374153533,3663,3713,3953,4273,5013,5833,6383,7193,7073,8673,9064,0753,1353,2103,2523,1382,9252,8962,9212,9572,9202,9202,9743,0723,4613,8783,6622,2072,3932,0371,4201,1071,1071,050976
       Property Plant Equipment 
976
1,050
1,107
1,107
1,420
2,037
2,393
2,207
3,662
3,878
3,461
3,072
2,974
2,920
2,920
2,957
2,921
2,896
2,925
3,138
3,252
3,210
3,135
4,042
3,857
3,818
3,707
3,719
3,638
3,583
3,501
3,427
3,395
3,371
3,322
0
0
0
0
3
3
3
2
2
2
2
2
2
2
1
1
123
433
607
591
565
538
511
610
571
533
496
459
466
431
406
368
354
333
455
422
390
376
363
390
399
358
354
35435839939036337639042245533335436840643146645949653357161051153856559160743312311222222233300003,3223,3713,3953,4273,5013,5833,6383,7193,7073,8183,8574,0423,1353,2103,2523,1382,9252,8962,9212,9572,9202,9202,9743,0723,4613,8783,6622,2072,3932,0371,4201,1071,1071,050976
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
41
37
37
49
49
54
67
63
63
63
78
94
121
147
190
200
243
265
269
268
281
292
296
299
366
365
379
411
441
488
501
518
549
463
494
519
499
517
505
506
516
5165065055174995194944635495185014884414113793653662992962922812682692652432001901471219478636363675449493737410000000000000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
394
0
0
0
0
0
0
0
0
92
0
0
0
0
0
0
25
0
0250000009200000000394000000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
27
28
24
24
2,015
21
99
514
401
886
772
1,001
813
788
788
1,032
1,061
1,165
1,213
1,125
1,649
1,580
1,476
1,678
1,676
1,811
1,836
1,771
1,614
1,538
1,458
1,474
1,533
1,105
1,017
789
38
63
55
177
284
377
479
514
379
85
92
96
69
72
44
130
500
132
185
130
63
120
346
353
470
281
203
277
195
225
201
282
223
1,198
404
254
204
271
1,209
400
1,917
1,575
1,5751,9174001,2092712042544041,198223282201225195277203281470353346120631301851325001304472699692853795144793772841775563387891,0171,1051,5331,4741,4581,5381,6141,7711,8361,8111,6761,6781,4761,5801,6491,1251,2131,1651,0611,0327887888131,00177288640151499212,01524242827
   > Total Current Liabilities 
27
28
24
24
2,015
21
99
514
401
886
772
277
76
26
26
1,032
1,061
1,090
1,138
1,050
973
981
877
1,079
1,676
1,811
1,836
1,711
1,555
1,478
1,399
1,415
1,473
1,046
957
789
38
63
55
177
284
332
434
469
334
40
92
96
69
72
44
130
500
132
185
130
63
91
226
242
399
221
153
238
166
207
194
282
223
1,056
268
125
82
156
1,099
298
1,822
1,488
1,4881,8222981,099156821252681,05622328219420716623815322139924222691631301851325001304472699692403344694343322841775563387899571,0461,4731,4151,3991,4781,5551,7111,8361,8111,6761,0798779819731,0501,1381,0901,0611,03226267627777288640151499212,01524242827
       Short-term Debt 
0
0
0
0
1,987
0
50
506
50
731
727
273
70
13
13
789
801
847
822
910
804
878
783
755
1,553
1,612
1,652
1,643
1,476
1,384
1,299
1,277
1,285
910
806
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12
36
37
45
46
47
48
49
50
85
40
29
32
28
51
53
55
56
58
29
30
30295856555351283229408550494847464537361200000000000000000000008069101,2851,2771,2991,3841,4761,6431,6521,6121,553755783878804910822847801789131370273727731505065001,9870000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
8
8
8
8
8
0
0
0
0
0
0
0
0
0
0
0
0
000000000000888888000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
27
28
0
19
2
0
22
4
19
120
19
3
0
0
0
0
0
0
0
137
167
101
92
322
122
197
182
67
77
92
98
136
186
134
150
109
36
61
33
70
46
66
90
74
26
13
33
60
63
63
14
108
26
87
31
89
56
43
45
13
135
164
60
173
61
90
26
163
180
985
225
92
48
121
1,058
262
1,279
1,447
1,4471,2792621,05812148922259851801632690611736016413513454356893187261081463636033132674906646703361361091501341861369892776718219712232292101167137000000031912019422021902827
       Other Current Liabilities 
0
0
0
5
26
20
27
5
332
35
25
2
6
0
13
243
260
243
316
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
680
2
2
22
108
238
257
331
373
283
7
43
25
6
9
29
22
473
26
89
41
8
42
97
156
216
7
45
9
22
19
52
68
10
25
15
-26
-26
-27
-28
-29
514
1,458
1,458514-29-28-27-26-2615251068521922945721615697428418926473222996254372833733312572381082222680222222222222222231624326024313062253533252720265000
   > Long-term Liabilities 
27
28
0
19
1,988
0
72
510
69
851
747
724
737
763
763
789
801
75
75
75
676
599
599
599
1,675
1,809
1,834
59
59
59
59
59
59
59
59
109
36
61
33
70
46
45
45
45
45
45
50
71
63
63
36
108
70
87
73
93
56
29
120
111
70
60
50
40
29
18
7
271
213
143
136
130
122
115
109
102
94
87
8794102109115122130136143213271718294050607011112029569373877010836636371504545454545467033613610959595959595959591,8341,8091,675599599599676757575801789763763737724747851695107201,9881902827
> Total Stockholder Equity
1,165
1,135
0
1,090
705
2,455
2,340
2,676
3,395
3,351
3,046
2,762
2,406
0
2,462
2,298
2,337
2,175
2,205
2,154
2,068
1,933
2,389
2,661
2,552
2,320
2,388
2,421
2,309
2,262
2,225
2,099
2,027
3,733
3,550
1,416
1,145
1,152
772
464
265
121
266
807
691
3,265
3,006
2,402
2,772
2,637
2,388
3,414
2,779
3,179
2,383
2,526
1,880
3,187
2,525
1,878
11,771
10,344
13,266
11,681
11,455
9,183
7,949
6,262
4,974
4,395
3,044
3,742
6,521
10,123
8,036
9,774
7,145
5,552
5,5527,1459,7748,03610,1236,5213,7423,0444,3954,9746,2627,9499,18311,45511,68113,26610,34411,7711,8782,5253,1871,8802,5262,3833,1792,7793,4142,3882,6372,7722,4023,0063,2656918072661212654647721,1521,1451,4163,5503,7332,0272,0992,2252,2622,3092,4212,3882,3202,5522,6612,3891,9332,0682,1542,2052,1752,3372,2982,46202,4062,7623,0463,3513,3952,6762,3402,4557051,09001,1351,165
   Common Stock
18
18
0
18
18
22
22
24
24
24
24
24
24
0
11
11
12
12
13
13
13
13
16
16
16
16
16
16
16
16
16
16
17
32
33
34
35
40
40
40
45
46
51
55
56
67
68
69
71
72
76
77
78
78
79
81
81
90
90
3
5
5
6
6
6
6
6
6
6
8
8
10
12
16
16
17
18
20
2018171616121088666666655390908181797878777672716968675655514645404040353433321716161616161616161616131313131212111102424242424242222181801818
   Retained Earnings -60,765-56,976-54,262-51,559-49,374-47,592-46,943-45,763-44,524-42,153-40,854-39,099-37,631-35,248-33,822-31,829-30,651-28,094-28,498-27,802-27,087-25,726-24,776-23,868-22,790-21,618-20,470-19,769-18,552-15,127-13,749-13,170-12,483-12,144-11,696-11,301-10,986-10,728-10,468-10,086-9,570-9,103-8,663-6,229-5,653-5,160-5,058-4,931-4,874-4,826-4,714-4,746-4,814-4,582-4,463-4,463-4,210-4,055-3,924-3,847-3,817-3,655-3,372-3,203-3,203-2,994-2,618-2,298-1,706-1,640-2,348-1,208-837-584-180-180-135-105
   Capital Surplus 000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
1,252
1,252
0
1,252
1,271
3,270
3,527
5,000
5,011
5,033
5,320
5,356
5,376
0
5,654
5,659
5,980
5,980
6,039
6,065
6,110
6,131
6,836
7,108
7,117
7,117
7,117
7,119
7,119
7,119
7,140
7,140
7,170
9,354
11,832
10,044
10,213
10,683
10,814
10,892
10,949
11,061
11,515
12,448
12,779
15,681
16,108
16,081
17,828
21,124
22,096
23,807
24,319
25,891
26,172
27,221
27,525
30,184
30,237
30,373
39,860
40,990
45,089
45,498
46,697
46,809
47,041
47,110
47,121
48,912
48,799
50,671
54,121
59,503
59,599
64,042
64,221
66,378
66,37864,22164,04259,59959,50354,12150,67148,79948,91247,12147,11047,04146,80946,69745,49845,08940,99039,86030,37330,23730,18427,52527,22126,17225,89124,31923,80722,09621,12417,82816,08116,10815,68112,77912,44811,51511,06110,94910,89210,81410,68310,21310,04411,8329,3547,1707,1407,1407,1197,1197,1197,1177,1177,1177,1086,8366,1316,1106,0656,0395,9805,9805,6595,65405,3765,3565,3205,0335,0115,0003,5273,2701,2711,25201,2521,252



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-08-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue464
Cost of Revenue-5
Gross Profit459459
 
Operating Income (+$)
Gross Profit459
Operating Expense-6,213
Operating Income-5,753-5,753
 
Operating Expense (+$)
Research Development2,361
Selling General Administrative3,852
Selling And Marketing Expenses0
Operating Expense6,2136,213
 
Net Interest Income (+$)
Interest Income14
Interest Expense-0
Other Finance Cost-0
Net Interest Income14
 
Pretax Income (+$)
Operating Income-5,753
Net Interest Income14
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-5,809-5,698
EBIT - interestExpense = -5,753
-5,795
-5,795
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-5,753-5,809
Earnings Before Interest and Taxes (EBITDA)-5,677
 
After tax Income (+$)
Income Before Tax-5,809
Tax Provision-0
Net Income From Continuing Ops-5,809-5,809
Net Income-5,795
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses6,217
Total Other Income/Expenses Net-56-14
 

Technical Analysis of Lexaria Bioscience Corp
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Lexaria Bioscience Corp. The general trend of Lexaria Bioscience Corp is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Lexaria Bioscience Corp's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Lexaria Bioscience Corp Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Lexaria Bioscience Corp.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.69 < 1.8955 < 1.911.

The bearish price targets are: 1.12 > 1.1 > 1.088.

Know someone who trades $LEXX? Share this with them.πŸ‘‡

Lexaria Bioscience Corp Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Lexaria Bioscience Corp. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Lexaria Bioscience Corp Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Lexaria Bioscience Corp. The current macd is 0.1018552.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Lexaria Bioscience Corp price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Lexaria Bioscience Corp. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Lexaria Bioscience Corp price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Lexaria Bioscience Corp Daily Moving Average Convergence/Divergence (MACD) ChartLexaria Bioscience Corp Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Lexaria Bioscience Corp. The current adx is 44.15.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Lexaria Bioscience Corp shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Lexaria Bioscience Corp Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Lexaria Bioscience Corp. The current sar is 1.01949384.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Lexaria Bioscience Corp Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Lexaria Bioscience Corp. The current rsi is 60.29. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending down: The RSI is trending down. -1
Lexaria Bioscience Corp Daily Relative Strength Index (RSI) ChartLexaria Bioscience Corp Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Lexaria Bioscience Corp. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Lexaria Bioscience Corp price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Lexaria Bioscience Corp Daily Stochastic Oscillator ChartLexaria Bioscience Corp Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Lexaria Bioscience Corp. The current cci is 151.59.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Lexaria Bioscience Corp Daily Commodity Channel Index (CCI) ChartLexaria Bioscience Corp Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Lexaria Bioscience Corp. The current cmo is 18.86.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Lexaria Bioscience Corp Daily Chande Momentum Oscillator (CMO) ChartLexaria Bioscience Corp Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Lexaria Bioscience Corp. The current willr is -44.23380727.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Lexaria Bioscience Corp is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Lexaria Bioscience Corp Daily Williams %R ChartLexaria Bioscience Corp Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Lexaria Bioscience Corp.

Lexaria Bioscience Corp Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Lexaria Bioscience Corp. The current atr is 0.11302507.

Lexaria Bioscience Corp Daily Average True Range (ATR) ChartLexaria Bioscience Corp Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Lexaria Bioscience Corp. The current obv is -123,766.

Lexaria Bioscience Corp Daily On-Balance Volume (OBV) ChartLexaria Bioscience Corp Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Lexaria Bioscience Corp. The current mfi is 65.10.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Lexaria Bioscience Corp Daily Money Flow Index (MFI) ChartLexaria Bioscience Corp Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Lexaria Bioscience Corp.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-04-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-14STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-15STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-10CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-06-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-06-24CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-07-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-14WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-22BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-07-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-31STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-08-06WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-14STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-26STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-09-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-09-12STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-15STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-16ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Lexaria Bioscience Corp Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Lexaria Bioscience Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5060.289
Ma 20Greater thanMa 501.003
Ma 50Greater thanMa 1000.930
Ma 100Greater thanMa 2000.972
OpenGreater thanClose1.470
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Lexaria Bioscience Corp with someone you think should read this too:
  • Are you bullish or bearish on Lexaria Bioscience Corp? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Lexaria Bioscience Corp? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Lexaria Bioscience Corp

I send you an email if I find something interesting about Lexaria Bioscience Corp.


Comments

How you think about this?

Leave a comment

Stay informed about Lexaria Bioscience Corp.

Receive notifications about Lexaria Bioscience Corp in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.